Arbutus Biopharma 관리
관리 기준 확인 3/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Mike McElhaugh
최고 경영자
US$1.6m
총 보상
| CEO 급여 비율 | 29.8% |
| CEO 임기 | 2yrs |
| CEO 소유권 | n/a |
| 경영진 평균 재임 기간 | 3.2yrs |
| 이사회 평균 재임 기간 | 6.1yrs |
최근 관리 업데이트
Recent updates
Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity
Jul 05Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up
May 23
Moderna Investors Should Beware Patent-Dispute Fallout
Apr 23Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Apr 10Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov 20Arbutus Biopharma: A First Assessment
Sep 15We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Jun 29CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$77m |
| Jun 30 2024 | n/a | n/a | -US$77m |
| Mar 31 2024 | n/a | n/a | -US$74m |
| Dec 31 2023 | US$2m | US$483k | -US$73m |
| Sep 30 2023 | n/a | n/a | -US$75m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$70m |
| Dec 31 2022 | US$1m | US$449k | -US$69m |
| Sep 30 2022 | n/a | n/a | -US$69m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$85m |
| Dec 31 2021 | n/a | n/a | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$87m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$1m | US$415k | -US$76m |
보상 대 시장: Mike 의 총 보상 ($USD 1.62M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 3.15M ).
보상과 수익: 회사가 수익성이 없는 동안 Mike 의 보상이 증가했습니다.
CEO
Mike McElhaugh (50 yo)
2yrs
테뉴어
US$1,620,485
보상
Mr. Michael J. McElhaugh, also known as Mike, co-founded Arbutus Biopharma Inc. in 2012 and serves as its Interim President and Chief Executive Officer and Director since January 1, 2024. Mr. McElhaugh had...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 2yrs | US$1.62m | 데이터 없음 | |
| Chief Scientific Officer | 9.8yrs | US$1.61m | 0.79% $ 5.1m | |
| CFO & Chief Accounting Officer | 6.4yrs | US$1.46m | 0.0088% $ 57.1k | |
| Vice President of Investor Relations | 3.2yrs | 데이터 없음 | 데이터 없음 | |
| General Counsel | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Human Resources | no data | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | 1.3yrs | 데이터 없음 | 0.0028% $ 18.0k | |
| Corporate Secretary | 14.5yrs | 데이터 없음 | 데이터 없음 |
3.2yrs
평균 재임 기간
60yo
평균 연령
경험이 풍부한 관리: ABUS 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | less than a year | US$1.62m | 데이터 없음 | |
| Independent Non-Executive Director | 9.9yrs | US$174.24k | 0.00053% $ 3.4k | |
| Independent Director | 7.7yrs | US$161.74k | 0% $ 0 | |
| Independent Non-Executive Director | 9.7yrs | US$156.74k | 0.024% $ 157.1k | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 6.1yrs | US$176.74k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 6.1yrs | 데이터 없음 | 데이터 없음 | |
| Independent Chairman of the Board of Directors | 6yrs | US$187.99k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 |
6.1yrs
평균 재임 기간
57.5yo
평균 연령
경험이 풍부한 이사회: ABUS 의 이사회는 경험(평균 재직 기간 6.1 년)으로 간주됩니다.